Neumora Therapeutics Inc (NMRA)
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions in the United States. The company’s lead program is navacaprant (NMRA-140), an oral once-daily kappa opioid receptor antagonist that is being evaluated in phase 3 trials for major depressive disorder. Neumora is also advancing NMRA-511 in phase 1 studies for agitation linked to dementia associated with Alzheimer’s disease. Its preclinical pipeline includes NMRA-NMDA and NMRA-M4R for schizophrenia, NMRA-CK1d for amyotrophic lateral sclerosis, NMRA-NLRP3 for certain neurodegenerative diseases, and NMRA-GCase for Parkinson’s disease. Formerly known as RBNC Therapeutics, the company adopted its current name in October 2021 and was incorporated in 2019. It is headquartered in Watertown, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NMRA
|
$2.13
|
28.9% Upside
|
Undervalued
|
$6.28
|
280.8% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-1.4x
|
4.3x
|
—
|
302 M
|
210.2 M
|
15.0%
|
61.4%
|
-12.8
|
—
|
87.0%
|
